Drug intelligence / Profile preview

A51R2

Development stage: Unknown
Lead developer: AJU Pharm
Modality: Small Molecules
Administration: Oral

Overview

A51R2 is an investigational pharmaceutical agent developed by AJU Pharm for the treatment of type 2 diabetes mellitus. It has been studied in clinical trials both as a monotherapy and in combination with another investigational agent, AJU-A51R1. The mechanism of action, molecular structure, and specific pharmacological class of A51R2 have not been publicly disclosed as of June 2025. Clinical studies have focused on evaluating its efficacy and safety profile in patients with type 2 diabetes mellitus[1][2][3][10].

Other names: AJU-A51R2AJU-A-51R2AJU-A 51R2

Beyond the preview

Go deeper on A51R2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A51R2.

Explore the full profile